, have been highlighted as: ? Of importance ?? Of major importance 1, Oram RA. Type 1 diabetes. Lancet, vol.391, pp.2449-62, 2018.
The epidemiology of type 1 diabetes in children, Endocrinol Metab Clin N Am, vol.41, issue.4, pp.679-94, 2012. ,
Epidemiology of type 1 diabetes, Endocrinol Metab Clin N Am, vol.39, issue.3, pp.481-97, 2010. ,
Incidence trends of type 1 and type 2 diabetes among youths, N Engl J Med, vol.376, issue.15, pp.1419-1448, 2002. ,
Updated 24-year trend of type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase, Diabet Med, vol.34, issue.9, pp.1252-1260, 2017. ,
Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia pediatric diabetes registry, Diabetes Care, vol.36, issue.6, pp.1597-603, 2013. ,
Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes, Diabetologia, vol.55, issue.7, pp.1937-1980, 2012. ,
Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study, Diabetes Care, vol.40, issue.9, pp.1194-202, 2017. ,
The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history on the progression from multiple autoantibodies to type 1 diabetes: a TEDDY study report, Diabetes, vol.66, issue.12, pp.3122-3131, 2017. ,
Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life, Diabetes, vol.62, issue.10, pp.3636-3676, 2013. ,
Understanding and preventing type 1 diabetes through the unique working model of TrialNet, Diabetologia, vol.60, issue.11, pp.2139-2186, 2017. ,
Strength in numbers: opportunities for enhancing the development of effective treatments for type 1 diabetes-the TrialNet experience, Diabetes, vol.67, issue.7, pp.1216-1241, 2018. ,
The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results, Pediatr Diabetes, vol.10, issue.2, pp.97-104, 2009. ,
Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial, JAMA, vol.318, pp.1891-902, 2017. ,
Incident dysglycemia and progression to type 1 diabetes among participants in the diabetes prevention trial-type 1, Diabetes Care, vol.32, issue.9, pp.1603-1610, 2009. ,
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report, Diabetes Care, vol.38, issue.10, pp.1975-85, 2015. ,
Validation of the diabetes prevention trial-type 1 risk score in the TrialNet natural history study, Diabetes Care, vol.34, issue.8, pp.1785-1792, 2011. ,
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes, Diabetes Care, vol.35, issue.7, pp.1552-1557, 2012. ,
Trends of earlier and later responses of Cpeptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants, Diabetes Care, vol.33, issue.3, pp.620-625, 2010. ,
Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1, Diabetes Care, vol.29, issue.3, pp.643-652, 2006. ,
? cell dysfunction exists more than 5 years before type 1 diabetes diagnosis, JCI Insight, vol.3, issue.15, p.120877, 2018. ,
Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr, Diabetes Care, vol.15, issue.8, pp.1009-1022, 1992. ,
The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1, Pediatr Diabetes, vol.19, issue.3, pp.403-412, 2018. ,
Insulin secretion in type 1 diabetes, Diabetes, vol.53, issue.2, pp.426-459, 2004. ,
Ethnicity and young age influence the frequency of diabetic ketoacidosis at the onset of type 1 diabetes, Diabetes Res Clin Pract, vol.78, issue.2, pp.259-62, 2007. ,
Finnish pediatric diabetes R. Age-related differences in the frequency of ketoacidosis at diagnosis of type 1 diabetes in children and adolescents, Diabetes Care, vol.33, issue.7, pp.1500-1502, 2010. ,
Shorter remission period in young versus older children with diabetes mellitus type 1, Exp Clin Endocrinol Diabetes, vol.115, issue.1, pp.33-40, 2007. ,
Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes, Pediatr Diabetes, vol.13, issue.7, pp.564-71, 2012. ,
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data, Diabetes, vol.61, issue.8, pp.2066-73, 2012. ,
Type 1 diabetes TrialNet study G. Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose, Diabetes Care, vol.39, issue.10, pp.1664-70, 2016. ,
C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase, Diabetes Care, vol.41, issue.7, pp.1486-92, 2018. ,
Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulindependent) diabetic children followed for two years from their clinical diagnosis, Diabetologia, vol.31, issue.9, pp.664-673, 1988. ,
The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom, Diabetologia, vol.29, issue.5, pp.267-74, 1986. ,
Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank for type 1 diabetes, Diabetes Metab Res Rev, vol.28, issue.7, pp.608-625, 2012. ,
Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study, Diabetologia, vol.57, issue.4, pp.841-844, 2014. ,
Beta-cell mass and turnover in humans: effects of obesity and aging, Diabetes Care, vol.36, issue.1, pp.111-118, 2013. ,
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans, Diabetes, vol.57, issue.6, pp.1584-94, 2008. ,
This study examines the persistence of pancreatic ? cells in donors with longstanding Type 1 diabetes donors from the nPOD collection and suggests that this is not due to ? cell regeneration, J Clin Endocrinol Metab, vol.102, issue.8, pp.2647-59, 2017. ,
Formation of a human beta-cell population within pancreatic islets is set early in life, J Clin Endocrinol Metab, vol.97, issue.9, pp.3197-206, 2012. ,
Adaptation of pancreatic islet cytoarchitecture during development, Phys Biol, vol.13, issue.2, p.25004, 2016. ,
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function, Proc Natl Acad Sci, vol.103, issue.7, pp.2334-2343, 2006. ,
Quantification of islet size and architecture, Islets, vol.4, issue.2, pp.167-72, 2012. ,
, Insulitis in human type 1 diabetes: the quest for an elusive lesion, Islets, vol.3, issue.4, pp.131-139, 2011.
Insulitis and beta-cell mass in the natural history of type 1 diabetes, Diabetes, vol.65, issue.3, pp.719-750, 2016. ,
Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes, Diabetes, vol.63, issue.11, pp.3835-3880, 2014. ,
This study demonstrates that age of onset of Type 1 diabetes (in recent-onset cases) is associated with different insulitic islet immune cell profiles and extent of pancreatic ?-cell destruction, Diabetes, vol.65, issue.6, pp.1362-1371, 2016. ,
Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus, PLoS One, vol.3, issue.1, p.1374, 2008. ,
Residual insulin production and pancreatic beta-cell turnover after 50 years of diabetes: Joslin medalist study, Diabetes, vol.59, issue.11, pp.2846-53, 2010. ,
Function of isolated pancreatic islets from patients at onset of type 1 diabetes; Insulin secretion can be restored after some days in a non-diabetogenic environment in vitro. Results from the DiViD study, Diabetes, vol.64, issue.7, pp.2506-2518, 2015. ,
Analysis of islet inflammation in human type 1 diabetes, Clin Exp Immunol, vol.155, issue.2, pp.173-81, 2009. ,
The diagnosis of insulitis in human type 1 diabetes, Diabetologia, vol.56, issue.11, pp.2541-2544, 2013. ,
Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?, Diabetologia, vol.60, issue.4, pp.753-758, 2017. ,
):eaao4013. This paper proposes that a universal state of 'benign' autoimmunity is present in all individuals. The key difference between the islet-reactive CD8+ T cells of T1D and healthy donors is not in their circulating frequency or history of antigen encounter, Sci Immunol, vol.3, issue.20, 2018. ,
Conventional and neo-antigenic peptides presented by beta cells are targeted by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors, Cell Metab, 2018. ,
,
, Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health, J Clin Invest, vol.113, issue.3, pp.451-63, 2004.
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes, Diabetes, vol.54, issue.5, pp.1407-1421, 2005. ,
CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion, Immunity, vol.43, issue.5, pp.896-908, 2015. ,
Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns, Nat Immunol, vol.17, issue.2, pp.187-95, 2016. ,
Elevations in the fasting serum Proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes, Diabetes Care, vol.39, issue.9, pp.1519-1545, 2016. ,
Evidence that the age at diagnosis of IDDM is genetically determined, Diabetes Care, vol.21, issue.6, pp.925-934, 1998. ,
Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States, Diabetologia, vol.44, issue.3, pp.354-62, 2001. ,
Evidence of gene-gene interaction and age-at-diagnosis effects in type 1 diabetes, Diabetes, vol.61, issue.11, pp.3012-3019, 2012. ,
The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5 years of age, Diabetologia, vol.61, issue.1, pp.147-57, 2018. ,
Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study, Diabetes Care, vol.27, issue.6, pp.1294-1302, 2004. ,
DOI : 10.2337/diacare.27.6.1294
URL : http://care.diabetesjournals.org/content/27/6/1294.full.pdf
Genetic analysis of adult-onset autoimmune diabetes, Diabetes, vol.60, issue.10, pp.2645-53, 2011. ,
Late-onset islet autoimmunity in childhood: the diabetes autoimmunity study in the young (DAISY), Diabetologia, vol.60, issue.6, pp.998-1006, 2017. ,
Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes, BMC Med, vol.15, issue.1, p.88, 2017. ,
Genetic risk scores for type 1 diabetes prediction and diagnosis, Curr Diab Rep, vol.17, issue.12, p.129, 2017. ,
DOI : 10.1007/s11892-017-0961-5
A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk, Diabetes Care, vol.41, issue.9, pp.1887-94, 2018. ,
Dissecting heterogeneity in paediatric type 1 diabetes: association of TCF7L2 rs7903146 TT and low-risk human leukocyte antigen (HLA) genotypes, Diabet Med, vol.34, issue.2, pp.286-90, 2016. ,
Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes, BMJ Open Diabetes Res Care, vol.2, issue.1, p.8, 2014. ,
TCF7L2 genetic variants contribute to phenotypic heterogeneity of type 1 diabetes, Diabetes Care, vol.41, issue.2, pp.311-318, 2018. ,
DOI : 10.2337/dc17-0961
URL : http://care.diabetesjournals.org/content/diacare/41/2/311.full.pdf
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass, Diabetologia, vol.53, issue.4, pp.614-637, 2010. ,
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebocontrolled Protege trial, Diabetes, vol.62, issue.11, pp.3901-3909, 2013. ,
DOI : 10.2337/db13-0236
URL : http://diabetes.diabetesjournals.org/content/62/11/3901.full.pdf
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial, Lancet Diabetes Endocrinol, vol.1, issue.4, pp.284-94, 2013. ,
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients, J Clin Invest, vol.125, issue.8, pp.3285-96, 2015. ,
DOI : 10.1172/jci81722
URL : http://www.jci.org/articles/view/81722/files/pdf
B-lymphocyte depletion, and preservation of beta-cell function, N Engl J Med, vol.361, issue.22, pp.2143-52, 2009. ,
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebocontrolled trial, Lancet, vol.378, issue.9789, pp.412-421, 2011. ,
DOI : 10.1016/s0140-6736(11)60886-6
URL : http://europepmc.org/articles/pmc3462593?pdf=render